Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 22%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc. is positioned favorably due to its extensive pipeline of gene therapies targeting inherited retinal diseases, with notable efficacy data demonstrating significant improvements in visual acuity and patient-reported outcomes. The recent updates from the European Medicines Agency (EMA) highlight a substantial increase in the incidence of clinically relevant improvements post-treatment, indicating a strong therapeutic potential. Moreover, the company's broad pipeline, which includes various preclinical assets, suggests substantial long-term growth opportunities, enhancing the positive outlook for Opus Genetics's stock as advancements in their therapies are anticipated.

Bears say

Opus Genetics Inc. faces significant risks associated with its pipeline of gene therapies for inherited retinal diseases, which may adversely impact the company's stock due to the potential for clinical failures that could delay approval or result in program discontinuation. The high incidence of adverse effects associated with its products, including endophthalmitis and notable declines in visual acuity, presents additional challenges that may deter patients from utilizing these therapies. Moreover, the lack of promising clinical outcomes, exemplified by documented declines in retinal thickness over time, raises concerns about the efficacy of Opus's treatments and their ability to meet market expectations.

Opus Genetics (IRD) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.